Inhibition of NF-κB by IKK16 circumvents resistance to multitargeted RTK inhibitors, such as sunitinib and sorafenib, in renal cell carcinoma cells [48]. The gene discussed is NFKB1; the disease is hereditary clear cell renal cell carcinoma.